Dr Raffaele Califano, Consultant Medical Oncologist
Dr Raffaele Califano
Consultant Medical Oncologist
Dr Raffaele Califano MD, Specialist Diploma in Medical Oncology
Consultant Medical Oncologist
Dr Raffaele Califano
Consultant Medical Oncologist MD, Specialist Diploma in Medical Oncology

Areas of expertise
- Thoracic malignancies
- Non-small cell lung cancer
- Small cell lung cancer
- Thymoma & thymic carcinoma
- Mesothelioma

About Dr Raffaele Califano
GMC number: 6153704
Year qualified: 2003
Place of primary qualification: Universita degli Studi di Perugia
Prof. Raffaele Califano is a Consultant Medical Oncologist at The Christie and an Honorary Professor at The University of Manchester, Manchester, UK. He graduated in Medicine and Surgery, summa cum laude, from the University of Perugia, Italy, in 2003 and completed his specialist training in Medical Oncology, summa cum laude, in 2007.
Prof. Califano is an esteemed investigator for clinical trials in lung cancer and mesothelioma. He has developed a particular interest in molecularly driven clinical trials and immunotherapy, contributing significantly to advancements in these areas. His expertise includes the treatment of non-small cell lung cancer, small cell lung cancer, and mesothelioma.
In addition to his clinical work, Prof. Califano is a prolific author, with several papers published in indexed peer-reviewed international journals. He is also a sought-after speaker, having been invited to present at numerous national and international oncology meetings.
Since his appointment, Prof. Califano has been dedicated to improving patient outcomes through innovative research and clinical excellence. His commitment to the field of oncology is evident in his ongoing efforts to explore new treatment modalities and improve existing therapies.
Areas of expertise
- Medical oncology
- Non small cell lung cancer
- Small cell lung cancer
- Thymoma
- Thymic carcinoma
- Mesothelioma
Professional memberships




Articles by Dr Raffaele Califano
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
Phase i trial of the mek inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer